Latest Articles about PPHM

Encouraging News for Peregrine Pharma - Analyst Blog

Zacks Equity Research — Fri, 24 May 2013 20:28:57 Z

Peregrine Pharmaceuticals ( PPHM ) recently received encouraging news when the company announced that the US Food and Drug Administration (FDA) has agreed on the design for the phase III

Encouraging News for Peregrine Pharma - Analyst Blog

Zacks Equity Research — Fri, 24 May 2013 03:26:41 Z

Peregrine Pharmaceuticals ( PPHM ) recently received encouraging news when the company announced that the US Food and Drug Administration (FDA) has agreed on the design for the phase III

Osiris Loss In-Line with Expectations - Analyst Blog

Zacks Equity Research — Thu, 09 May 2013 02:24:53 Z

Osiris Loss In-Line with Expectations Osiris Therapeutics Inc. ( OSIR ) reported a first-quarter 2013 loss of 8 cents per share, in-line with the Zacks Consensus Estimate but wider than

Peregrine Reports Narrower Loss - Analyst Blog

Zacks Equity Research — Thu, 14 Mar 2013 02:14:18 Z

Peregrine Pharmaceuticals, Inc. ( PPHM ) reported a net loss of 4 cents per share in the third quarter of fiscal 2013 (ended Jan 31, 2013), narrower than the year-ago loss of 13 cents and

Update on Peregrine's Bavituximab - Analyst Blog

Zacks Equity Research — Wed, 20 Feb 2013 23:50:01 Z

Peregrine Pharmaceuticals, Inc. ( PPHM ) recently announced updated data on bavituximab from its randomized, double-blind placebo-controlled phase II trial that was conducted in patients

Largest option buying in equities so far

David Russell — Tue, 19 Feb 2013 21:06:06 Z

Nearing the halfway mark in today's session, here are the individual equity names with the most call and put buying on optionMONSTER's ActionTracker data system. Peregrine Pharmaceuticals

Data on Peregrine's Bavituximab - Analyst Blog

Zacks Equity Research — Fri, 15 Feb 2013 02:00:01 Z

Peregrine Pharmaceuticals ( PPHM ) recently announced phase II data on its oncology candidate, bavituximab. The open-label, randomized phase II study was conducted in patients suffering

Priority FDA Review for Celgene Drug - Analyst Blog

Zacks Equity Research — Wed, 13 Feb 2013 02:40:01 Z

Recently, Celgene Corporation ( CELG ) announced that the US Food and Drug Administration (FDA) will review the supplemental New Drug Application (sNDA) for cancer drug Revlimid

Gilead Closes YM Biosciences Buyout - Analyst Blog

Zacks Equity Research — Tue, 12 Feb 2013 04:13:01 Z

Recently, Gilead Sciences, Inc. ( GILD ) completed its acquisition of Canada-based drug development company, YM BioSciences Inc. for $2.95 per share. Through this acquisition, Gilead aims

Protalix Exploring Options - Analyst Blog

Zacks Equity Research — Fri, 08 Feb 2013 04:15:01 Z

Protalix BioTherapeutics, Inc. ( PLX ) recently confirmed that it has hired Citigroup, Inc. ( C ) to explore strategic options. Protalix, an Israel-based biopharmaceutical company,

Pipeline Setback for Idenix - Analyst Blog

Zacks Equity Research — Fri, 08 Feb 2013 03:10:01 Z

Idenix Pharmaceuticals, Inc. ( IDIX ) recently announced that the company has decided to discontinue its clinical development program for IDX184. IDX184 is a nucleotide polymerase

Medivation's Xtandi Impresses - Analyst Blog

Zacks Equity Research — Fri, 08 Feb 2013 02:30:01 Z

Medivation, Inc. ( MDVN ) recently announced that its partner Astellas Pharma Inc. ( ALPMY ) reported Xtandi (enzalutamide) sales of about $57 million in the US for the quarter ended

Vivus Unveils Qsymia Study Results - Analyst Blog

Zacks Equity Research — Thu, 07 Feb 2013 23:40:01 Z

Vivus Inc. ( VVUS ) recently announced the publication of results from a study regarding its weight-loss drug, Qsymia. Results from the study revealed that the weight loss arising from

Gilead Beats Estimates in 4Q - Analyst Blog

Zacks Equity Research — Tue, 05 Feb 2013 19:30:01 Z

Gilead Sciences, Inc. 's ( GILD ) fourth quarter 2012 earnings (excluding special items but including stock option expense) of 47 cents per share beat the Zacks Consensus Estimate of 45

Canada Approves Seattle Genetics' Adcetris - Analyst Blog

Zacks Equity Research — Tue, 05 Feb 2013 03:44:21 Z

Seattle Genetics Inc. ( SGEN ) recently received approval from Health Canada for its oncology drug, Adcetris (brentuximab vedotin). Adcetris has been approved under Health Canada's Notice